Buy IMVT: IMVT-1402 Is the Reason to Re-rate Immunovant Now
Immunovant (IMVT) is upgraded to Buy after recent evidence and corporate moves that increase the probability IMVT-1402 becomes a multi-indication FcRn franchise. The setup combines a crowded but expanding autoimmune market, upcoming near-term readouts (RA topline expected H2 2026) and improved technical momentum. This is a high-risk, potentially hi…